Huizinga Robert Bindert
- SEC CIK
- 0001837648
No open-market purchases or sales filed in the past year.
Current role at each company
- AUPH Aurinia Pharmaceuticals Inc.EVP of Researchas of Mar 4, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Huizinga Robert Bindert as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Huizinga Robert BindertEVP of Research | SSale | −4.85K | $12.01 | −$58.2K | −6.5%69.4K after | |
| Oct 26, 2021 (view filing) | Oct 25 | 1 day | Huizinga Robert BindertEVP of Research | SSale | −130.0K | $29.75 | −$3.87M | −66.4%65.7K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Huizinga Robert BindertEVP of Research | SSale | −32.5K | $23.99 | −$779.5K | −24.4%100.7K after | 2 lots |
| Sep 14, 2021 (view filing) | Sep 10-14 | 4 days | Huizinga Robert BindertEVP of Research | SSale | −32.5K | $21.15 | −$687.3K | −23.5%106.1K after | 3 lots |
| Sep 8, 2021 (view filing) | Sep 7 | 1 day | Huizinga Robert BindertEVP of Research | SSale | −5.00K | $18.30 | −$91.5K | −3.5%138.6K after |